Get the Stockscreener App
0.49
3.16%
0.015
Talphera Inc stock is traded at $0.49, with a volume of 8,615.
It is up +3.16% in the last 24 hours and down -22.80% over the past month.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
See More
Previous Close:
$0.475
Open:
$0.476
24h Volume:
8,615
Relative Volume:
0.15
Market Cap:
$10.67M
Revenue:
$2.82M
Net Income/Loss:
$-14.20M
P/E Ratio:
-0.5765
EPS:
-0.85
Net Cash Flow:
$-15.13M
1W Performance:
-5.86%
1M Performance:
-22.80%
6M Performance:
-53.07%
1Y Performance:
-50.51%
1-Day Range:
$0.476
$0.51
1-Week Range:
$0.453
$0.535
52-Week Range:
$0.45
$1.27
Talphera Inc Stock (TLPH) Company Profile
Compare TLPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.49 | 10.67M | 2.82M | -14.20M | -15.13M | -0.85 |
|
ZTS
Zoetis Inc
|
146.85 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.19 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.31 | 15.25B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.25 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-20-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-11-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-05-19 | Resumed | Credit Suisse | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Outperform |
| Apr-24-19 | Resumed | B. Riley FBR | Buy |
| Feb-15-19 | Initiated | Credit Suisse | Outperform |
| Oct-23-18 | Initiated | B. Riley FBR | Buy |
| Oct-13-17 | Downgrade | Jefferies | Buy → Hold |
| Oct-13-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-14-17 | Resumed | Jefferies | Buy |
| Sep-15-16 | Reiterated | ROTH Capital | Buy |
| Aug-05-16 | Downgrade | Stifel | Buy → Hold |
| Oct-30-15 | Upgrade | Jefferies | Hold → Buy |
| Oct-05-15 | Reiterated | ROTH Capital | Buy |
| Sep-02-15 | Initiated | H.C. Wainwright | Buy |
| Jul-10-15 | Resumed | ROTH Capital | Buy |
| May-06-15 | Reiterated | Mizuho | Neutral |
| May-05-15 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-10-15 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-09-15 | Downgrade | Mizuho | Buy → Neutral |
View All
Talphera Inc Stock (TLPH) Latest News
HC Wainwright Predicts Talphera’s Q1 Earnings (NASDAQ:TLPH) - Defense World
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
HC Wainwright Estimates Talphera FY2029 Earnings - Defense World
Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com India
Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks
Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com
Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World
Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada
Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India
Talphera: Q4 Earnings Snapshot - CT Insider
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance
Talphera Reports 2024 Financial Results and Study Update - TipRanks
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India
FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK
TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
TALPHERA, INC. SEC 10-K Report - TradingView
Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA approves Talphera’s reduced NEPHRO CRRT study size - Investing.com India
Talphera reports Q4 EPS (7c) vs. (25c) last year - TipRanks
FDA Green Light: Talphera Slashes Trial Size by 58% as Q4 Losses Drop 57% - Stock Titan
TLPH stock touches 52-week low at $0.5 amid market challenges - Investing.com
Talphera to Reduce Size of Renal Replacement Therapy Study, Enters Private Placement; Shares Fall - MarketScreener
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million - PR Newswire
Earnings Outlook For Talphera - Benzinga
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 - Longview News-Journal
Talphera to Unveil 2024 Performance: Key Financial Results and Strategic Updates Coming March 31 - Stock Titan
Talphera Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Talphera (TLPH) Expected to Announce Earnings on Wednesday - Defense World
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock By Investing.com - Investing.com South Africa
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock - Investing.com
Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened - Armenian Reporter
Talphera Inc (NASDAQ: TLPH) Is On The Rise - Stocks Register
RODMAN&RENSHAW Upgrades Talphera (NASDAQ:TLPH) to Strong-Buy - Defense World
Rodman & Renshaw sets Talphera stock Buy rating, $4 target - MSN
Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright - Defense World
FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada
FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria
FDA to review Talphera's request to amend NEPHRO study - Investing.com
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - The Eastern Progress Online
TLPH stock touches 52-week low at $0.6 amid market shifts - Investing.com UK
TLPH stock touches 52-week low at $0.61 amid market challenges - Investing.com
Talphera faces Nasdaq delisting over share price rule - Investing.com
Talphera faces Nasdaq delisting over share price rule By Investing.com - Investing.com UK
Acelrx Announces Dsuvia® Milestone C Approval; Provides Revenue Guidance for the First Quarter 2020 - Marketscreener.com
Talphera Inc Stock (TLPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):